Killing of Giardia lamblia trophozoites by human intestinal fluid in vitro
Related Experiment Videos
1Department of Pathology, University of California, San Diego Medical Center 92103.
The Journal of Infectious Diseases
|June 1, 1988
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
[Clinicopathological characteristics of early gastric cardiac carcinoma from specimens of endoscopic submucosal dissection].
Zhonghua bing li xue za zhi = Chinese journal of pathology·2026
[Mid-term efficacy evaluation of transcatheter mitral valve "valve-in-valve" replacement with different access approaches for degenerated bioprosthesis at single-center].
Zhonghua wai ke za zhi [Chinese journal of surgery]·2026
[Guidance for the use of prophylactic monoclonal antibodies against respiratory syncytial virus in primary care].
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
[Consistency of claudin 18.2 expression with antibodies of different clones in gastric adenocarcinoma].
Zhonghua bing li xue za zhi = Chinese journal of pathology·2025
[Application of PMS2 and MSH6 double-antibody detection in screening of mismatch repair deficient tumors].
Zhonghua bing li xue za zhi = Chinese journal of pathology·2025
Transplantation and the HIV Latent Viral Reservoir.
The Journal of infectious diseases·2026
Potential Synergistic Association of Donepezil and Metformin With COVID-19 Mortality in Dementia Patients.
The Journal of infectious diseases·2026
Obesity in Children is Associated With Increased Dengue Virus Binding, but not Neutralizing, Antibody Responses Following Primary Infection.
The Journal of infectious diseases·2026
A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4.
The Journal of infectious diseases·2026
IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19.
The Journal of infectious diseases·2026
A novel injectable drug-combination nanoparticle containing three antiretrovirals designed for HIV treatment: A first-in-human trial.
The Journal of infectious diseases·2026